TY - JOUR
T1 - Mediterranean Diet and Atherothrombosis Biomarkers
T2 - A Randomized Controlled Trial
AU - Hernáez, Álvaro
AU - Castañer, Olga
AU - Tresserra-Rimbau, Anna
AU - Pintó, Xavier
AU - Fitó, Montserrat
AU - Casas, Rosa
AU - Martínez-González, Miguel Ángel
AU - Corella, Dolores
AU - Salas-Salvadó, Jordi
AU - Lapetra, José
AU - Gómez-Gracia, Enrique
AU - Arós, Fernando
AU - Fiol, Miquel
AU - Serra-Majem, Lluis
AU - Ros, Emilio
AU - Estruch, Ramón
N1 - Funding Information:
This work was supported by grants of Instituto de Salud Carlos III [OBN17PI02, PIE14/00045_INFLAMES, CB06/03/0019, CB06/03/0028, and CD17/00122 (A.H.)], and Agència de Gestió d'Ajuts Universitaris i de Recerca (2017 SGR 222).
Funding Information:
The authors wish to thank Daniel Muñoz‐Aguayo, Gemma Blanchart, and Sònia Gaixas for their technical assistance, and Stephanie Lonsdale for revising the English text. J.S.‐S. gratefully acknowledges the financial support by ICREA under the ICREA Academia program. CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN) is an initiative of the Instituto de Salud Carlos III, Madrid, Spain, and financed by the European Regional Development Fund.
Funding Information:
This work was supported by grants of Instituto de Salud Carlos III [OBN17PI02, PIE14/00045_INFLAMES, CB06/03/0019, CB06/03/0028, and CD17/00122 (A.H.)], and Ag?ncia de Gesti? d'Ajuts Universitaris i de Recerca (2017 SGR 222). The authors wish to thank Daniel Mu?oz-Aguayo, Gemma Blanchart, and S?nia Gaixas for their technical assistance, and Stephanie Lonsdale for revising the English text. J.S.-S. gratefully acknowledges the financial support by ICREA under the ICREA Academia program. CIBER de Fisiopatolog?a de la Obesidad y Nutrici?n (CIBEROBN) is an initiative of the Instituto de Salud Carlos III, Madrid, Spain, and financed by the European Regional Development Fund.
Publisher Copyright:
© 2020 Wiley-VCH GmbH
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Scope: To assess whether following a Mediterranean diet (MedDiet) improves atherothrombosis biomarkers in high cardiovascular risk individuals. Methods and results: In 358 random volunteers from the PREvención con DIeta MEDiterránea trial, the 1-year effects on atherothrombosis markers of an intervention with MedDiet, enriched with virgin olive oil (MedDiet-VOO; n = 120) or nuts (MedDiet-Nuts; n = 119) versus a low-fat control diet (n = 119), and whether large increments in MedDiet adherence (≥3 score points, versus compliance decreases) and intake changes in key food items are associated with 1-year differences in biomarkers. Differences are observed between 1-year changes in the MedDiet-VOO intervention and control diet on the activity of platelet activating factor acetylhydrolase in high-density lipoproteins (HDLs) (+7.5% [95% confidence interval: 0.17; 14.8]) and HDL-bound α1-antitrypsin levels (−6.1% [−11.8; −0.29]), and between the MedDiet-Nuts intervention and the control arm on non-esterified fatty acid concentrations (−9.3% [−18.1; −0.53]). Large MedDiet adherence increments are associated with less fibrinogen (−9.5% [−18.3; −0.60]) and non-esterified fatty acid concentrations (−16.7% [−31.7; −1.74]). Increases in nut, fruit, vegetable, and fatty fish consumption, and decreases in processed meat intake are linked to enhancements in biomarkers. Conclusion: MedDiet improves atherothrombosis biomarkers in high cardiovascular risk individuals.
AB - Scope: To assess whether following a Mediterranean diet (MedDiet) improves atherothrombosis biomarkers in high cardiovascular risk individuals. Methods and results: In 358 random volunteers from the PREvención con DIeta MEDiterránea trial, the 1-year effects on atherothrombosis markers of an intervention with MedDiet, enriched with virgin olive oil (MedDiet-VOO; n = 120) or nuts (MedDiet-Nuts; n = 119) versus a low-fat control diet (n = 119), and whether large increments in MedDiet adherence (≥3 score points, versus compliance decreases) and intake changes in key food items are associated with 1-year differences in biomarkers. Differences are observed between 1-year changes in the MedDiet-VOO intervention and control diet on the activity of platelet activating factor acetylhydrolase in high-density lipoproteins (HDLs) (+7.5% [95% confidence interval: 0.17; 14.8]) and HDL-bound α1-antitrypsin levels (−6.1% [−11.8; −0.29]), and between the MedDiet-Nuts intervention and the control arm on non-esterified fatty acid concentrations (−9.3% [−18.1; −0.53]). Large MedDiet adherence increments are associated with less fibrinogen (−9.5% [−18.3; −0.60]) and non-esterified fatty acid concentrations (−16.7% [−31.7; −1.74]). Increases in nut, fruit, vegetable, and fatty fish consumption, and decreases in processed meat intake are linked to enhancements in biomarkers. Conclusion: MedDiet improves atherothrombosis biomarkers in high cardiovascular risk individuals.
KW - Mediterranean diet
KW - atherothrombosis
KW - biomarkers
KW - cardiovascular risk
KW - clinical trials
UR - http://www.scopus.com/inward/record.url?scp=85091690563&partnerID=8YFLogxK
U2 - 10.1002/mnfr.202000350
DO - 10.1002/mnfr.202000350
M3 - Article
C2 - 32918853
AN - SCOPUS:85091690563
SN - 1613-4125
VL - 64
JO - Molecular Nutrition and Food Research
JF - Molecular Nutrition and Food Research
IS - 20
M1 - 2000350
ER -